

**New York State Medicaid
Drug Utilization Review (DUR) Board
Meeting Summary for April 24, 2014**

The Medicaid DUR Board met on Thursday April 24, 2014 from 9:00 AM to 4:30 PM
Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

An archived audio cast of the meeting proceedings is available on the Department of Health website:
<http://www.health.ny.gov/events/webcasts/>

A. Welcome and Introductions

(Audio Cast Time 26:05 – 28:18)

Department of Health

Janet Zachary-Elkind

Robert Correia, PharmD

Anthony Merola, RPh, MBA

John Naioti, RPh

Robert Sheehan, RPh

Monica Toohey, RPh

DUR Board

Leigh Briscoe-Dwyer, PharmD

Donna Chiefari, PharmD

Jadwiga Najib, PharmD

Anita Radix, MD

Michelle Rainka, PharmD

James Saperstone, MD

William Scheer, RPh

John Wikiera

Office of Mental Health

Gregory Miller, MD

Catherine Benham, RPh, MS

Magellan Medicaid Administration

Eileen Zimmer, PharmD, MBA

B. Public Comment Period

(Audio Cast Time 28:19 – 1:54:15)

The following speakers provided public comment to the Board:

- | | | | |
|----|---------------------------|-----------------------------|----------------------------------|
| 1. | William Seidel, PhD | UCB | Anticonvulsants - 2nd Generation |
| 2. | Robert A Mead, PharmD | Eisai Inc. | Anticonvulsants - 2nd Generation |
| 3. | Maria Cannito, PharmD, MS | Pfizer Primary Care Medical | Anticonvulsants - 2nd Generation |
| 4. | John Richter, MPA | Mental Health Association | Antipsychotics - 2nd Generation |
| 5. | Adrian Morris, MD | Private Practice | Antipsychotics - 2nd Generation |

6.	Matthew Shapiro	NAMI-NYS	Antipsychotics - 2nd Generation
7.	Ellen Schoonover, NP	Albany County Mental Health	Antipsychotics - 2nd Generation
8.	Thomas Qualtere, MD	Schenectady Mental Health Assn.	Antipsychotics - 2nd Generation
9.	David Crandall, PhD	Sunovion Pharmaceuticals	Antipsychotics - 2nd Generation
10.	Oliver Lopena, PharmD	Otsuka America	Antipsychotics - 2nd Generation
11.	Amanda Williams, PharmD	Forest Research Institute	Antipsychotics - 2nd Generation
12.	Parris Pope, PharmD	Jazz	Antipsychotics - 2nd Generation
13.	Catherine Datto, MD, MS	AstraZeneca Pharmaceuticals	Antipsychotics - 2nd Generation
14.	Dorothea Sanchez, PhD	Sunovion Pharmaceuticals	Carbamazepine Derivatives
15.	Maria Cannito, PharmD, MS	Pfizer Primary Care Medical	Central Nervous System Stimulants
16.	Andy Kim, PharmD	Shire	Central Nervous System Stimulants
17.	Robert Garris, PharmD, MPH	Teva	Multiple Sclerosis Agents
18.	Beth D'Ambrosio, PharmD	Novartis Pharmaceuticals, Inc.	Multiple Sclerosis Agents
19.	Richard Able, Jr, PhD	Genzyme	Multiple Sclerosis Agents
20.	Margaret Fisher, PharmD	Novo Nordisk Inc.	Growth Hormones
21.	Matt Goodwin	Salix Pharmaceuticals Inc.	Sulfasalazine Derivatives
22.	Furqan Tejani MD	State University of New York	Platelet Inhibitors
23.	Marisa Winther, PharmD	AstraZeneca Pharmaceuticals	Platelet Inhibitors
24.	Ashish Trivedi, PharmD	Eli Lilly	Platelet Inhibitors
25.	Arlene Price, PharmD	Janssen Scientific Affairs	Immunomodulators - systemic
26.	Carol Himelein, PharmD	UCB	Immunomodulators - systemic
27.	John Holtz, PhD	Pfizer Primary Care Medical	Immunomodulators - systemic
28.	Shallini Hede, PharmD	BMS	Immunomodulators - systemic
29.	Maria Dugandzic, PharmD	Boehringer Ingelheim Pharm	Anticholinergics/COPD Agents
30.	Michelle Kamdar, PharmD	GSK	Anticholinergics/COPD Agents
31.	Michelle Kamdar, PharmD	GSK	Corticosteroids - Inhaled
32.	Lori Baylor, PhD	AstraZeneca	Corticosteroid/LABA Combinations
33.	Robert Garris, PharmD, MPH	Teva	Corticosteroids - intranasal

C. Preferred Drug Program Clinical Reviews

(Audio Cast Time 2:12:06 – 3:59:25)

Eileen Zimmer, PharmD

Robert Correia, PharmD

1. Anticonvulsants - Second Generation

(Audio Cast Time 2:14:28)

2. Antipsychotics - Second Generation

(Audio Cast Time 2:22:10)

3. Carbamazepine Derivatives	(Audio Cast Time 2:30:26)
4. CNS Stimulants	(Audio Cast Time 2:33:50)
5. Multiple Sclerosis Agents	(Audio Cast Time 2:37:46)
6. Selective Serotonin Reuptake Inhibitors	(Audio Cast Time 2:42:52)
7. Selective Norepinephrine Reuptake Inhibitors	(Audio Cast Time 2:49:10)
8. Antifungals - Topical	(Audio Cast Time 2:53:15)
9. Anti-infectives - Topical ¹	(No clinical review)
10. Growth Hormones ¹	(No clinical review)
11. Thiazolidinediones	(Audio Cast Time 2:56:15)
12. Sulfasalazine Derivatives	(Audio Cast Time 2:59:00)
13. Platelet Inhibitors	(Audio Cast Time 3:06:23)
14. Immunomodulators - Systemic	(Audio Cast Time 3:17:55)
15. Alpha-2 Adrenergic Agonists - Ophthalmic	(Audio Cast Time 3:27:32)
16. Prostaglandin Agonists	(Audio Cast Time 3:30:40)
17. Phosphate Binders/Regulators	(Audio Cast Time 3:33:25)
18. Anticholinergics/COPD Agents	(Audio Cast Time 3:36:53)
19. Antihistamines - Second Generation ¹	(No clinical review)
20. Corticosteroids - Inhaled	(Audio Cast Time 3:42:15)
21. Corticosteroid/LABA Combinations	(Audio Cast Time 3:46:02)
22. Corticosteroids - Intranasal ¹	(No clinical review)
23. Prescription NSAIDs	(Audio Cast Time 3:50:27)
24. Opioids - Long Acting	(Audio Cast Time 3:54:52)

¹ Therapeutic classes for which no clinical review was presented as no new pertinent clinical information was known to exist since the previous review of the class.

Note: Although listed on the agenda, the Hepatitis C – Direct Acting Antivirals therapeutic class was not reviewed during the meeting.

E. Executive Session

(Recess to Executive Session Audio Cast Time 4:00:40)

The Board recessed the public session at 12:45 pm to go into executive session for review of financial information relating to each of the therapeutic classes under review. No official action was taken in the executive session. The Board reconvened to the public session at 3:00 pm.

F. DUR Board Recommendations

(Audio Cast Time 6:27:28 – 6:52:28)

Based on the clinical and financial information, the Board unanimously (unless otherwise noted) recommended the following to the Commissioner of Health for final determination:

Recommendations of DUR Board	Commissioner's Final Determination
<p>Prescription NSAIDs 6:30:50</p> <p>Preferred diclofenac sodium, diclofenac sodium XR, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meloxicam, nabumetone, naproxen, naproxen sodium, naproxen EC, piroxicam, sulindac, Voltaren Gel</p> <p>Non-preferred Anaprox, Anaprox DS, Arthrotec, Cambia, Celebrex, Cataflam, Daypro, diclofenac potassium, diclofenac/misoprostol, diflunisal, Duexis, etodolac, etodolac ER, Feldene, fenoprofen, Flector, Indocin suspension, indomethacin SR, ketoprofen SA, meclofenamate, mefenamic acid, Mobic, Naprelan, Naprosyn, Naprosyn EC, oxaprozin, Pennsaid, Ponstel, Sprix, tolmetin, Vimovo, Voltaren XR, Zipsor, Zorvolex</p>	<p style="text-align: center;">Approved as Recommended</p>
<p>Opioids – Long Acting 6:32:55</p> <p>Preferred fentanyl patch, Kadian, morphine sulfate SR tablet</p> <p>Non-preferred Avinza, Butrans, Conzip, Duragesic, Exalgo, morphine sulfate ER capsule, MS Contin, Nucynta ER, Opana ER, Oxycontin, oxymorphone ER, Ryzolt ER, tramadol ER, Ultram ER, Zohydro ER</p>	<p style="text-align: center;">Approved as Recommended</p>

<p>Anticonvulsants – Second Generation 6:33:35</p> <p>Preferred Felbatol, gabapentin capsule, gabapentin solution, Gabitril 2mg & 4mg, lamotrigine, levetiracetam, levetiracetam ER, Lyrica, Topiragen, topiramate, zonisamide</p> <p>Non-preferred Banzel, felbamate, Fycompa, gabapentin tablet, Gabitril 12mg & 16mg, Keppra, Keppra XR, Lamictal, Lamictal XR, lamotrigine XR, Neurontin, Onfi, Potiga, Sabril, tiagabine, Topamax, Trokendi XR, Vimpat, Zonegran</p>	<p>Approved as Recommended</p>
<p>Antipsychotics – Second Generation 6:34:11</p> <p>Preferred clozapine, Fanapt, Latuda, olanzapine tablet, quetiapine, risperidone, Saphris, Seroquel XR, ziprasidone</p> <p>Non-preferred Abilify, clozapine ODT, Clozaril, Fazaclor, Geodon, Invega, olanzapine ODT, Risperdal, Seroquel, Versacloz, Zyprexa</p>	<p>Approved as Recommended</p>
<p>Carbamazepine Derivatives 6:34:47</p> <p>Preferred carbamazepine chewable, carbamazepine tablet, Carbatrol, Epitol, Equetro, oxcarbazepine tablet, Tegretol chewable, Tegretol suspension, Tegretol XR, Trileptal suspension</p> <p>Non-preferred Aptiom, carbamazepine ER, carbamazepine XR, carbamazepine suspension, oxcarbazepine suspension, Oxtellar XR, Tegretol tablet, Trileptal tablet</p>	<p>Approved as Recommended</p>

<p>CNS Stimulants 6:35:20</p> <p>Preferred Adderall, Adderall XR, amphetamine salt combo IR, dexamylphenidate, dextroamphetamine, Focalin XR, Metadate ER, Methylin, methylphenidate tablet, methylphenidate ER, methylphenidate SR (tablet), Vyvanse</p> <p>Non-preferred amphetamine salt combo ER, Concerta, Daytrana, Desoxyn, Dexedrine spansule, dexamylphenidate XR, dextroamphetamine ER, dextroamphetamine solution, Focalin, Metadate CD, methamphetamine, methylphenidate CD, methylphenidate ER capsule, methylphenidate solution, modafinil, Nuvigil, Procentra, Provigil, Quillivant XR, Ritalin, Ritalin LA, Ritalin SR, Zenedi</p> <p>Vote: 7 support, 1 oppose, 1 abstention</p> <p>DOH recommendation modified by making Quillivant XR a non-preferred product.</p>	<p>Approved as Recommended</p>
<p>Multiple Sclerosis Agents 6:38:00</p> <p>Preferred Avonex, Copaxone 20mg/ml, Extavia</p> <p>Non-preferred Aubagio, Betaseron, Copaxone 40mg/ml, Gilenya, Rebif, Tecfidera</p>	<p>Approved as Recommended</p>
<p>Selective Serotonin Reuptake Inhibitors 6:38:54</p> <p>Preferred citalopram, escitalopram tablet, fluoxetine (10mg, 20mg, 40mg), fluoxetine solution, paroxetine, sertraline</p> <p>Non-preferred Brintellix, Brisdelle, Celexa, escitalopram solution, fluoxetine 60mg, fluoxetine DR, fluvoxamine, fluvoxamine ER, Lexpro, Luvox CR, paroxetine CR, Paxil, Paxil CR, Pexeva, Prozac, Sarafem, Viibryd, Zoloft</p>	<p>Approved as Recommended</p>

<p>Serotonin Norepinephrine Reuptake Inhibitors 6:39:25</p> <p>Preferred Cymbalta, venlafaxine, venlafaxine ER capsule</p> <p>Non-preferred desvenlafaxine ER, Effexor XR, Fetzima, Khedezla, Pristiq, Savella, venlafaxine ER tablet</p>	<p>Approved as Recommended</p>
<p>Antifungals - Topical 6:39:54</p> <p>Preferred Drugs clotrimazole OTC, Lamisil AT Cream OTC, miconazole OTC, Nyamyc, nystatin cream/ointment, nystatin powder, nystatin/triamcinolone, Nystop, Pedi-Dri, terbinafine OTC, tolnaftate OTC</p> <p>Non-preferred Drugs Ciclodan, ciclopirox, clotrimazole Rx, clotrimazole/betamethasone, econazole, Ertaczo, Exelderm, Extina, ketoconazole, Ketodan, Loprox, Lotrisone, Luzu, Mentax, Naftin, Oxistat, Vusion,</p>	<p>Approved as Recommended</p>
<p>Anti-infectives – Topical 6:40:24</p> <p>Preferred Benzaclin pump, clindamycin gel, clindamycin lotion, clindamycin solution, erythromycin gel, erythromycin solution</p> <p>Non-preferred Acanya, Akne-mycin, Benzaclin gel, Benzamycin, Cleocin T, Clindagel, clindamycin/benzoyl peroxide, clindamycin foam, clindamycin swab, Duac, Erygel, erythromycin swab, erythromycin/benzoyl peroxide, Evoclin</p>	<p>Approved as Recommended</p>
<p>Growth Hormone 6:41:09</p> <p>Preferred Gentotropin, Norditropin, Nutropin, Nutropin AQ,</p> <p>Non-preferred Humatrope, Omnitrope, Saizen, Tev-tropin, Zorbtive</p>	<p>Approved as Recommended</p>

<p>Thiazolidinediones 6:41:38</p> <p>Preferred pioglitazone</p> <p>Non-preferred Actoplus Met, Actoplus Met XR, Actos, Avandamet, Avandaryl, Avandia, Duetact, pioglitazone/glimepiride, pioglitazone/metformin</p>	<p>Approved as Recommended</p>
<p>Sulfasalazine Derivatives 6:42:09</p> <p>Preferred Apriso, Delzicol, Dipentum, sulfasalazine DR, sulfasalazine IR, sulfazine, sulfazine EC</p> <p>Non-preferred Asacol HD, Azulfidine, Azulfidine Entab, balsalazide, Colazal, Giazol, Lialda, Pentasa</p>	<p>Approved as Recommended</p>
<p>Platelet Inhibitors 6:42:43</p> <p>Preferred Aggrenox, Brilinta, clopidogrel, dipyridamole, Effient</p> <p>Non-preferred Persantine, Plavix, ticlopidine</p> <p>Vote: 5 support, 4 oppose</p> <p>DOH recommendation modified by making Brilinta a preferred product.</p>	<p>Approved as Recommended</p>
<p>Immunomodulators - Systemic 6:44:55</p> <p>Preferred Enbrel, Humira</p> <p>Non-preferred Actemra SQ, Cimzia, Kineret, Orencia SQ, Simponi, Stelara, Xeljanz</p>	<p>Approved as Recommended</p>

<p>Alpha-2 Adrenergic Agonists - Ophthalmic (for Glaucoma) 6:45:22</p> <p>Preferred Alphagan, brimonidine 0.2%, Simbrinza</p> <p>Non-preferred apraclonidine, brimonidine 0.15%, Iopidine</p>	<p>Approved as Recommended</p>
<p>Prostaglandin Agonists - Ophthalmic 6:45:59</p> <p>Preferred latanoprost</p> <p>Non-preferred Lumigan, Rescula, Travatan Z, travopost, Xalatan, Zioptan</p>	<p>Approved as Recommended</p>
<p>Phosphate Binders/Regulators 6:46:31</p> <p>Preferred calcium acetate, Eliphos, Fosrenol, Renagel</p> <p>Non-preferred Phoslo, Phoslyra, Renvela, Velphoro</p>	<p>Approved as Recommended</p>
<p>Anticholinergics/COPD Agents 6:47:12</p> <p>Preferred Atrovent HFA, Combivent , ipratropium, ipratropium/albuterol, Spiriva</p> <p>Non-preferred Anoro Ellipta, Daliresp, Duoneb, Tudorza</p>	<p>Approved as Recommended</p>

<p>Antihistamines - Second Generation 6:47:35</p> <p>Preferred cetirizine OTC tablet, cetirizine OTC 1mg/1ml solution, Claritin OTC solution, loratadine OTC</p> <p>Non-preferred cetirizine OTC chewable, cetirizine solution Rx, cetirizine OTC 5mg/5ml solution, cetirizine-D OTC, Claritin OTC chewable, Clarinex, Clarinex-D, Claritin OTC capsule, Claritin OTC ODT, Claritin OTC tablet, Claritin-D OTC, desloratadine, fexofenadine OTC, fexofenadine Rx, levocetirizine, loratadine-D OTC, Xyzal</p> <p>Vote: 8 support, 1 oppose</p> <p>DOH recommendation modified by making Claritin OTC chewable a non-preferred product.</p>	<p>Approved as Recommended</p>
<p>Corticosteroids - Inhaled 6:50:47</p> <p>Preferred Asmanex, Flovent Diskus, Flovent HFA, Pulmicort Flexhaler, Qvar</p> <p>Non-preferred Areospan, Alvesco</p>	<p>Approved as Recommended</p>
<p>Corticosteroids/Long Acting Beta Agonist Combinations 6:51:16</p> <p>Preferred Advair Diskus, Advair HFA, Dulera, Symbicort</p> <p>Non-preferred Breo Ellipta</p>	<p>Approved as Recommended</p>
<p>Intranasal Corticosteroids 6:51:44</p> <p>Preferred fluticasone, Nasonex</p> <p>Non-preferred Beconase AQ, Dymista, Flonase, flunisolide, Nasacort AQ, Omnaris. Qnasl, Rhinocort Aqua, triamcinolone, Veramyst, Zetonna</p>	<p>Approved as Recommended</p>

G. Final Comments and Adjournment

Audio Cast Time (6:52:33 – 6:53:32)

Janet Zachary Elkind
Anthony Merola, RPh, MBA

Meeting adjourned at 3:30 PM

F. Commissioner Final Determinations

The impact of this final determination is as follows:

1. State Public Health Population:
 - Minimal effect on Medicaid enrollees, as a large majority of enrollees currently utilize preferred products.
 - Non-preferred products remain available with prior authorization.
2. Program Providers:
 - No impact on prescribers when utilizing preferred products. Prescribers, or their agents, will need to initiate the prior authorization process when ordering non-preferred products.
3. State Health Program:
 - Annual gross savings associated with these therapeutic classes under the PDP are estimated at \$4.5M. The savings are achieved through changes in utilization to equally effective and less expensive products including the receipt of supplemental rebates from pharmaceutical manufacturers.